

MacroGenics Completes Follow-on Offering of Common Stock

Proceeds to fund clinical development of multiple assets

Zurich (Switzerland), February 12, 2014 – MacroGenics Inc. (NASDAQ:MGNX) raised \$65.7 million through the sale of 1.8 million shares at \$36.50 in a follow-on underwritten by BofA Merrill Lynch; Leerink; Stifel; Wedbush PacGrow; and Roth Capital Partners. MacroGenics proposed to raise up to \$90 million in the offering on Jan. 30, when its share price was \$38.90. On Monday, the company said it planned to sell 1.5 million shares in the offering. Shareholders raised \$43.8 million through the sale of 1.2 million shares in a concurrent secondary offering.

MacroGenics' margetuximab (MGAH22), a Fc optimized mAb against HER2, is in a Phase IIa trial to treat metastatic breast cancer. Next half, the company plans to start a Phase III trial for margetuximab to treat advanced gastroesophageal cancer.

MacroGenics, which priced the offering after market close on Wednesday, was up \$0.83 to \$38 on the day.

(BioCentury 2014)

About MacroGenics, Inc.

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.

For more information, please contact:

Alfred Scheidegger

PhD, Founding Partner & CEO

Nextech Invest Ltd.

Tel.: +41 44 366 66 12

scheidegger@nextechinvest.com

www.nextechinvest.com